Menu Search
Equities

Sandoz Group AG

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0SAN:LSE

Sandoz Group AG

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CHF)65.89
  • Today's Change0.281 / 0.43%
  • Shares traded12.10k
  • 1 Year change+47.30%
  • Beta--
Data delayed at least 20 minutes, as of Feb 16 2026 11:05 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.

  • Revenue in CHF (TTM)8.12bn
  • Net income in CHF174.20m
  • Incorporated2022
  • Employees23.41k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		SDZ:SWX since
announced		Transaction
value
Just - Evotec Biologics EU SASDeal completed30 Jul 202530 Jul 2025Deal completed38.57%750.43m
Data delayed at least 15 minutes, as of Feb 16 2026 11:23 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.